csirt@kutim:~/threat-intel/cve/CVE-2020-3320

Katalog CVE

CVSS 5.4 · Medium EPSS 0,63%

Kerentanan Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') pada cisco secure firewall management center, cisco sourcefire defense center. Skor CVSS 3.1 5.4 (Medium) menurut NVD.

Deskripsi (NVD)

A vulnerability in the web-based management interface of Cisco Firepower Management Center could allow an authenticated, remote attacker to conduct a cross-site scripting (XSS) attack against a user of the web-based management interface of an affected device. The vulnerability is due to insufficient validation of user-supplied input by the web-based management interface of an affected device. An attacker could exploit this vulnerability by first entering input within the web-based management interface and then persuading a user of the interface to view the crafted input within the interface. A successful exploit could allow the attacker to execute arbitrary script code in the context of the affected interface or access sensitive, browser-based information.

Rincian

Terbit di NVD
8 Oktober 2020
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
5.4 (Medium), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
EPSS (30 hari)
0,63% peluang dieksploitasi; lebih tinggi dari 48,9% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
cisco secure firewall management center Semua versi hingga 6.6.1
cisco sourcefire defense center Versi 6.4.0
cisco sourcefire defense center Versi 6.4.0.6
cisco sourcefire defense center Versi 6.5.0
cisco sourcefire defense center Versi 6.6.0

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.